NZ509174A - Use of polynucleotides encoding NAB1 and NAB2 in wound healing - Google Patents

Use of polynucleotides encoding NAB1 and NAB2 in wound healing

Info

Publication number
NZ509174A
NZ509174A NZ509174A NZ50917499A NZ509174A NZ 509174 A NZ509174 A NZ 509174A NZ 509174 A NZ509174 A NZ 509174A NZ 50917499 A NZ50917499 A NZ 50917499A NZ 509174 A NZ509174 A NZ 509174A
Authority
NZ
New Zealand
Prior art keywords
nab2
polypeptide
nab1
nucleic acid
egr
Prior art date
Application number
NZ509174A
Other languages
English (en)
Inventor
Martin Braddock
Callum Jeffrey Campbell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814989.1A external-priority patent/GB9814989D0/en
Priority claimed from GBGB9819826.0A external-priority patent/GB9819826D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NZ509174A publication Critical patent/NZ509174A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ509174A 1998-07-11 1999-07-09 Use of polynucleotides encoding NAB1 and NAB2 in wound healing NZ509174A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814989.1A GB9814989D0 (en) 1998-07-11 1998-07-11 Gene therapy method
GBGB9819826.0A GB9819826D0 (en) 1998-09-12 1998-09-12 Gene therapy method
PCT/GB1999/002199 WO2000003014A1 (en) 1998-07-11 1999-07-09 Pharmaceutical uses of nab1 and nab2

Publications (1)

Publication Number Publication Date
NZ509174A true NZ509174A (en) 2003-08-29

Family

ID=26314007

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ509174A NZ509174A (en) 1998-07-11 1999-07-09 Use of polynucleotides encoding NAB1 and NAB2 in wound healing

Country Status (22)

Country Link
EP (1) EP1097200A1 (id)
JP (1) JP2002520020A (id)
KR (1) KR20010071832A (id)
CN (1) CN1317045A (id)
AP (1) AP2001002038A0 (id)
AU (1) AU763713B2 (id)
BR (1) BR9912018A (id)
CA (1) CA2336805A1 (id)
EA (1) EA200100028A1 (id)
EE (1) EE200100020A (id)
HR (1) HRP20010025A2 (id)
HU (1) HUP0102835A3 (id)
ID (1) ID27742A (id)
IL (1) IL140533A0 (id)
IS (1) IS5788A (id)
NO (1) NO20010166L (id)
NZ (1) NZ509174A (id)
PL (1) PL345507A1 (id)
SK (1) SK382001A3 (id)
TR (1) TR200100622T2 (id)
WO (1) WO2000003014A1 (id)
YU (1) YU1901A (id)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928430D0 (en) * 1999-12-01 2000-01-26 Glaxo Group Ltd Screening
AU2001291019A1 (en) 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
WO2004083435A1 (en) * 2003-03-17 2004-09-30 Julius-Maximilians-Uni Versität Würzburg Nab proteins and their use in diagnostic and therapeutic applications in heart disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection

Also Published As

Publication number Publication date
HRP20010025A2 (en) 2001-12-31
NO20010166L (no) 2001-03-06
NO20010166D0 (no) 2001-01-10
IL140533A0 (en) 2002-02-10
SK382001A3 (en) 2001-09-11
IS5788A (is) 2000-12-22
AP2001002038A0 (en) 2001-03-31
EP1097200A1 (en) 2001-05-09
YU1901A (sh) 2005-06-10
CA2336805A1 (en) 2000-01-20
AU763713B2 (en) 2003-07-31
KR20010071832A (ko) 2001-07-31
HUP0102835A2 (hu) 2001-11-28
EE200100020A (et) 2002-06-17
TR200100622T2 (tr) 2001-10-22
CN1317045A (zh) 2001-10-10
HUP0102835A3 (en) 2003-09-29
PL345507A1 (en) 2001-12-17
BR9912018A (pt) 2006-01-31
ID27742A (id) 2001-04-26
EA200100028A1 (ru) 2001-08-27
JP2002520020A (ja) 2002-07-09
WO2000003014A1 (en) 2000-01-20
AU4791499A (en) 2000-02-01

Similar Documents

Publication Publication Date Title
EP0759067B1 (en) Transforming growth factor alpha h1
EP2298336A9 (en) Promotion of epithelial regeneration
EP1083934B1 (en) EGR-1 for the manufacture of a medicament for treating wounds
US20030103956A1 (en) Use of HIF-1a variants to accelerate wound healing
AU763713B2 (en) Pharmaceutical uses of NAB1 and NAB2
ZA200100193B (en) Pharmaceutical uses of NAB1 and NAB2.
US7157439B2 (en) HoxD3, HoxA3, and HoxB3 compositions and methods for improved wound healing
MXPA01000386A (en) Pharmaceutical uses of nab1 and nab2
CZ2001142A3 (cs) Použití molekuly nukleové kyseliny
US7115582B2 (en) HoxD3 and HoxA3 compositions and methods for improved wound healing
JPWO2009116529A1 (ja) ポリペプチドおよび当該ポリペプチドを含む医薬組成物
ZA200006963B (en) Gene therapy method.
CZ20004509A3 (cs) Způsob genové terapie
MXPA00011726A (en) Gene therapy method
KR20110095611A (ko) Mic―1 유전자 또는 그의 발현 단백질을 함유하는 상처 치료용 약학적 조성물

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed